ANIP
NASDAQ · Pharmaceuticals
Ani Pharmaceuticals Inc
$67.79
-1.83 (-2.63%)
Financial Highlights (FY 2026)
Revenue
981.67M
Net Income
87.06M
Gross Margin
61.4%
Profit Margin
8.9%
Rev Growth
+40.8%
D/E Ratio
1.14
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 61.4% | 61.4% | 50.7% | 50.7% |
| Operating Margin | 12.6% | 11.3% | 18.0% | 18.0% |
| Profit Margin | 8.9% | 8.4% | 13.1% | 14.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 981.67M | 697.16M | 587.23M | 677.58M |
| Gross Profit | 602.35M | 427.78M | 297.61M | 343.40M |
| Operating Income | 123.49M | 78.93M | 105.58M | 122.17M |
| Net Income | 87.06M | 55.64M | 76.98M | 94.84M |
| Gross Margin | 61.4% | 61.4% | 50.7% | 50.7% |
| Operating Margin | 12.6% | 11.3% | 18.0% | 18.0% |
| Profit Margin | 8.9% | 8.4% | 13.1% | 14.0% |
| Rev Growth | +40.8% | +40.8% | +23.0% | +20.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 426.20M | 426.20M | 377.30M | 386.46M |
| Total Equity | 373.40M | 373.40M | 736.99M | 759.49M |
| D/E Ratio | 1.14 | 1.14 | 0.51 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 225.05M | 151.83M | 125.34M | 137.44M |
| Free Cash Flow | — | — | 59.62M | 74.72M |